A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.
Clinical trial NCT05845138 · UNKNOWN
Trial details
- NCT number
- NCT05845138
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-25
- Primary completion
- 2024-12-31
- Enrollment
- 116
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.